Future Of Renal Denervation On Trial At ACC 2014 This Weekend
This article was originally published in The Gray Sheet
Executive Summary
The full results of Medtronic’s SYMPLICITY HTN-3 trial, to be presented at the American College of Cardiology Scientific Sessions on March 29, could determine the fate of the renal denervation devices under development by several major companies for drug-resistant hypertension.
You may also be interested in...
Medtronic Nabs First Superiority Outcome In TAVR Versus Surgery
Data from Medtronic’s CoreValve High Risk Study provide the firm with significant momentum toward expanding the FDA label for its transcatheter aortic valve replacement device. Based on the results, FDA says no advisory panel will need to meet for the firm’s high-risk surgery submission. Observers say the jury is still out on CoreValve versus Sapien question.
Full Medtronic Results Offer Little Reason For Optimism On Renal Denervation
Renal denervation did not have a significant effect on systolic blood pressure in the SYMPLICITY HTN-3 trial, the first major sham-controlled trial of renal denervation for drug-resistant hypertension. The trial’s sponsor, Medtronic, had previously announced that it missed its primary endpoint but full results of the study were presented for the first time at the ACC meeting in Washington, DC on March 29.
News Briefs: FDA Approves AF Catheter; Tax Reform Proposal; Renal Denervation
FDA approved a PMA supplement for Biosense Webster’s Thermocool SmartTouch, the first FDA-approved ablation catheter that can measure contact force in real time. J&J earns a CE mark for its Renlane renal denervation system. More news briefs.